Summary of SI-BONE FY Conference Call (March 02, 2026) Company Overview - **Company**: SI-BONE (NasdaqGM:SIBN) - **Industry**: MedTech, specifically focused on orthopedic solutions for SI joint dysfunction and related conditions Key Points and Arguments Company Evolution and Product Portfolio - SI-BONE has transitioned from a single product company focused on SI joint dysfunction to a diversified portfolio addressing multiple disease states related to compromised bone [3][5] - The company has developed technologies such as Granite for deformity and TNT for trauma, expanding its offerings beyond the original Triangle product [6][10] Market Strategy and Growth - The company aims to leverage its biomechanical engineering expertise to target markets with unmet needs and high failure rates in existing treatments [6][7] - SI-BONE has achieved a compound annual growth rate (CAGR) of about 20% since its IPO, significantly outperforming the overall orthopedic market growth [31][32] - The trauma market represents a $300 million total addressable market (TAM), while the overall TAM for SI-BONE is $3.5 billion [15][16] Partnership with Smith & Nephew - The partnership with Smith & Nephew is expected to enhance SI-BONE's reach in trauma surgery, allowing access to a larger segment of trauma surgeons [15][18] - This collaboration is designed to free up SI-BONE's sales representatives to focus on larger TAMs in spine and interventional markets [15][22] Product Launches and Innovations - SI-BONE is set to launch several new products, including INTRA Ti, which is designed to improve workflow efficiency for interventionalists [38][45] - The company has a robust pipeline of innovations, including a third Breakthrough Device expected to be filed for 510(k) approval in Q3 2026 [50][51] Financial Guidance and Market Trends - The company anticipates a deceleration in top-line growth for 2026 compared to 2025, but cites significant tailwinds such as increased reimbursement rates and new product launches [34][35] - Reimbursement for the allograft product is expected to increase by 20%-30% due to new policies, which will positively impact revenue [36][37] Operational Focus - The new COO, Anshul Maheshwari, emphasizes growth, field efficiency, and operational improvements to maintain high gross margins (currently at 78%-79%) [40][41] - The company is focused on reducing administrative burdens on sales representatives to enhance productivity [40][41] Long-term Outlook - SI-BONE is positioned for sustained growth with a focus on addressing unmet needs in the orthopedic market, particularly in compromised bone conditions [58][59] - The company plans to launch new products regularly over the next five years, targeting high failure rate procedures to expand its market presence [57][60] Additional Important Insights - The company has seen record numbers of interventionalists and trauma doctors performing procedures, indicating strong market traction [32][33] - SI-BONE's strategy includes maintaining a capital-light model while focusing on differentiated technologies with high gross margins [60][62]

Core Insights - Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company focused on developing therapies for unmet medical needs in CNS, inflammatory, and cardiometabolic diseases [1][4] - The company will participate in a fireside chat and KOL webinar on October 10, 2025, featuring discussions on schizophrenia treatment and clinical data for its lead drug candidate, brilaroxazine [1][2] Company Overview - Reviva's pipeline includes two drug candidates: brilaroxazine (RP5063) and RP1208, both of which are new chemical entities discovered in-house [4] - The company has secured composition of matter patents for both drug candidates in the United States, Europe, and several other countries [4]

Core Insights - MediciNova, Inc. is nearing completion of patient randomization in its Phase 2/3 COMBAT-ALS trial, with only single-digit enrollment remaining [2][3] - The company is also seeking the final two patients for its Phase 2 trial targeting dyslipidemia and fatty liver disease in type 2 diabetes patients [2][3] - The COMBAT-ALS program has generated significant interest within the ALS community, and the company is preparing for regulatory discussions with the FDA, expecting top-line data by the end of next year [3] MediciNova's Development Programs - MN-166 (ibudilast) is in late-stage clinical development for neurodegenerative diseases, including ALS, and has received Orphan Drug Designation and Fast Track Designation from the FDA [4] - MN-001 (tipelukast) is being developed for fibrotic and metabolic disorders, showing promise in down-regulating genes that promote fibrosis and inflammation [5] - The company focuses on addressing unmet medical needs in difficult-to-treat conditions through its development activities [6] Funding and Strategic Development - MediciNova's strategy includes advancing its pipeline through various funding sources, including investigator-sponsored trials, government grants, and strategic alliances [7]